BATON ROUGE, La., and BANNOCKBURN, Ill., Jan. 05, 2021 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and personal care, and Option Care Health Inc. (NASDAQ: OPCH), the nation’s largest independent home and alternate site infusion services provider, are collaborating on providing COVID antibody infusion therapy within skilled nursing and assisted living facilities, collectively referred to as “long term care facilities.” The U.S Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUAs) to both Eli Lilly and Regeneron for their investigational neutralizing antibody therapies to treat mild to moderate COVID-19 in adults and pediatrics who are at high risk for progressing to severe COVID-19 symptoms or hospitalization.
On December 8, 2020, the National Home Infusion Association (NHIA) announced it had launched a pilot program with Operation Warp Speed and the department of Health and Human Services to expand access to Bamlanivimab for COVID-19-positive eligible patients residing in long-term care facilities. As an active member of the NHIA, Option Care Health agreed to participate in the pilot program to help service this vulnerable population.
Through the collaboration, which will initially be piloted in Indianapolis and Valparaiso, Indiana markets, with potential to scale to other markets, as appropriate, Amedisys and Option Care Health will coordinate to expeditiously provide care to long-term care facility residents. This innovative service model draws on the strengths and capabilities of both organizations and leverages clinical resources in the most efficient way to ensure expanded access to this difficult-to-serve population. Through its Hospice division, Amedisys will oversee the on-site care coordination for residents through their expansive clinical team. Option Care Health will leverage its pharmacy network operations to provide critical clinical pharmacy oversight and will distribute Bamlanivimab through its national network of pharmacies.
John Rademacher, Chief Executive Officer of Option Care Health, stated, “We are proud to collaborate with Amedisys, a leader in home health and hospice services, along with NHIA and leaders of Operation Warp Speed, to expand access to vital therapies for one of the most vulnerable populations. Combining the extraordinary capabilities of two industry leaders to solve a critical healthcare challenge is truly humbling.”
“We have experience from being on the frontlines and caring for more than 12,500 COVID 19-positive patients,” stated Paul Kusserow, President and Chief Executive Officer of Amedisys. “We know how important innovative solutions are for caring for those who need our services the most, and this is exactly the type of partnerships in which Amedisys wants to be involved to help our country make it through this pandemic. We’re extremely honored to play our part alongside Option Care Health, NHIA and Operation Warp Speed.”
Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,600 hospitals and 67,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, Tenn., Amedisys is a publicly held company. With 21,000 employees in 514 care centers within 39 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 415,000 patients and clients in need every year. For more information about the Company, please visit: www.amedisys.com.
关于 Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 5,000 teammates, including approximately 2,900 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates.
When included in this press release, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “would,” “should,” “will” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic (“COVID-19”), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, widespread protest or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.
For Investor Inquiries:
Bob East, Asher Dewhurst, Jordan Kohnstam